Last reviewed · How we verify

NCT04682743

Prevention of Post-Operative Shivering

Completed EARLY_PHASE1 Last updated 31 March 2022
What this trial tests

EARLY_PHASE1 trial testing paracetamol in Post-Operative Shivering in 120 participants. Completed in 22 February 2022.

Timeline
6 January 2021
Primary endpoint
16 January 2022
22 February 2022

Quick facts

Lead sponsorCairo University
PhaseEARLY_PHASE1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment120
Start date6 January 2021
Primary completion16 January 2022
Estimated completion22 February 2022
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Cairo University

Who can join

Adults 18 to 40, any sex, with Post-Operative Shivering. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Shivering and vasoconstriction are thermoregulatory mechanisms that are required to increase core body temperature (BT) in patients with core hypothermia. paracetamol is an antipyretic drug that has been in clinical use for a long time. It can lower the BT of febrile and nonfebrile patients. A previous study demonstrated that orally administered paracetamol can suppress in a dose-dependent manner the increase in the BT of patients with acute ischemic stroke. However, few studies have evaluated the effects of paracetamol on postoperative shivering.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of paracetamol

Trials testing the same drug.

Other Cairo University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04682743.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing